Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huangqin total aglycone capsule is a botanical drug candidate derived from the roots of *Scutellaria baicalensis* (Huangqin). It contains a purified mixture of flavonoid aglycones, primarily baicalein, wogonin, and oroxylin A. Developed by China Pharmaceutical University, the drug is being evaluated for the treatment of NIH category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), specifically targeting the 'damp-heat in the lower burner' pattern in Traditional Chinese Medicine. The mechanism involves anti-inflammatory and antioxidant activities, likely through the inhibition of pro-inflammatory cytokines and modulation of oxidative stress pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huangqin total aglycone capsule.